




pepper bio

THE END OF UNTREATABLE



Patients need to be lucky in order to be treated effectively





I have been there, when my grandmother got Alzheimer's, where there are no treatments





Pepper team has the scientific rigor and business acumen for success



SAMANTHA DALE STRASSER, PHD
CSO & Co-founder
PhD, MIT

- Developed Pepper's technology
- Studied multi-omics while an NSF Graduate Research Fellow in EECS mentored by Douglas Lauffenburger at MIT
- Former Churchill Scholar and Goldwater Scholar



JON HU
CEO & Co-founder
MBA, Harvard Business School

- Led Atidiv (formerly Loft), an enterprise solutions Guild portfolio company, as its CEO, growing the company from 200 to 300 people
- Expanded Techweek, a tech conference and Guild portfolio company, to 2 new cities as COO



SIMON FRICKER, PHD
CDO
PhD, University of Warwick

- 25+ years of experience in the industry from a founding member of AnorMED (acquired by Genzyme) to Sanofi
- Worked on 3 approved drugs, including overseeing a drug from beginning to approval





Industry researchers identified 3 fundamental problems with drug discovery

Static

Studies lack functional information and focus on 'what is there' not 'what is happening'

Biased

Researchers often look in the wrong places when using limited panels

Correlative


Analyses miss causative interactions and depth



Pepper's transomics approach ushers in a new era of drug discovery



Traditional R&D




Phosphoproteomics.....

Modified protein data provides a **functional** understanding of biology

..... Proteomics

... Transcriptomics ...

..... Genomics



Global data across all layers captures full complexity of biology

Incorporating universal interactions reveal **causal** relationships



Pepper's platform exceeds state-of-the-art target ID approaches in cancer

12x

Better than leading
NLP of over 30M+
scientific sources

4x

Better than traditional
multiomic analyses

2 key questions in drug development for patients



Right target?

Does the target cause disease?
Can regulating the target reverse disease?




Right drug?

Does the drug hit the target?
Does the drug hit something it shouldn't?



Our tech addresses both key questions




Understand disease
(What drives or sustains disease)



Understand drug
(Full impact of drug on patient)



We can apply our technology to nearly the entire process and can integrate seamlessly into pharma's existing processes





Platform can be applied across 3 large therapeutic areas

Oncology


\$201B (2021) | 9.7% CAGR

1 out of 6 people worldwide dies due to cancer.

Neurodegenerative

\$34B (2020) | 4.9% CAGR

1 out of 9 people worldwide dies due to a disorder of the nervous system.



Inflammatory diseases

\$98B (2020) | 9.3% CAGR

3 out of 5 people worldwide die due to chronic inflammatory diseases.

Only 1 out of 50 people worldwide lives to reach the age of 80.



We can generate early revenue while developing our pipeline



Develop drugs internally

Product engine to churn out new drugs

- Strong, fast tech validation
- High value capture
- High control



Develop partnerships

Partner-of-choice for pharma

- High patient impact and access
- Early & recurring revenue
- Robust data & platform validation




We're starting in oncology by looking at 3 cancers worth \$5.3B for our internal pipeline

		Addressable population (US & EU5)	Pricing assumptions	Total Addressable Market (US & EU5)
Lymphoma Myc-driven		8.4K	US: \$250K EU: \$93K	\$1.5B
Liver cancer Myc-driven		10.7K	US: \$182K EU: \$98K	\$1.5B
NSCLC EGFRm (top 4 atypical + SoC-resistant)		14.8K	US: \$182K EU: \$98K	\$2.3B



We expect to reach the clinic in HCC next year





We already generate revenue through partnerships



\$3.3B

\$1B+

Scalable partnerships
(Low R&D effort)

Recurring & early revenue
(Embed Pepper into pharma's existing processes)

Short-term total addressable market
(Pre-clinical omics R&D tech in oncology, neurology, and inflammatory)

Jumbo-sized platform deals in the market
(e.g., Roche, Bayer, BMS, Gilead)